Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 451

1.

Secukinumab immunogenicity over 52 weeks in patients with psoriatic arthritis and ankylosing spondylitis.

Deodhar A, Gladman DD, McInnes IB, Spindeldreher S, Martin R, Pricop L, Porter B, Safi J Jr, Shete A, Bruin G.

J Rheumatol. 2019 Jun 15. pii: jrheum.190116. doi: 10.3899/jrheum.190116. [Epub ahead of print]

PMID:
31203228
2.

Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study.

Glatt S, Taylor PC, McInnes IB, Schett G, Landewé R, Baeten D, Ionescu L, Strimenopoulou F, Watling MIL, Shaw S.

Ann Rheum Dis. 2019 Jun 8. pii: annrheumdis-2018-214943. doi: 10.1136/annrheumdis-2018-214943. [Epub ahead of print]

3.

Association of central adiposity with psoriasis, psoriatic arthritis and rheumatoid arthritis: a cross-sectional study of the UK Biobank.

Ferguson LD, Brown R, Celis-Morales C, Welsh P, Lyall DM, Pell JP, McInnes IB, Siebert S, Sattar N.

Rheumatology (Oxford). 2019 May 25. pii: kez192. doi: 10.1093/rheumatology/kez192. [Epub ahead of print]

PMID:
31131407
4.

Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients with Psoriatic Arthritis: A Pooled Analysis Across Phase 3 and Long-Term Extension Studies.

Gladman DD, Charles-Schoeman C, McInnes IB, Veale DJ, Thiers B, Nurmohamed M, Graham D, Wang C, Jones T, Wolk R, Demasi R.

Arthritis Care Res (Hoboken). 2019 May 21. doi: 10.1002/acr.23930. [Epub ahead of print]

PMID:
31112005
5.

Serum CRP, IL-17A, and IL-17F levels are responsive to ustekinumab in psoriatic arthritis: lessons from the PSUMMIT study programme.

Siebert S, Sweet K, Dasgupta B, Campbell K, McInnes IB, Loza MJ.

Arthritis Rheumatol. 2019 May 9. doi: 10.1002/art.40921. [Epub ahead of print]

PMID:
31070869
6.

Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data.

Deodhar A, Mease PJ, McInnes IB, Baraliakos X, Reich K, Blauvelt A, Leonardi C, Porter B, Das Gupta A, Widmer A, Pricop L, Fox T.

Arthritis Res Ther. 2019 May 2;21(1):111. doi: 10.1186/s13075-019-1882-2.

7.

Fibroblast activation and inflammation in frozen shoulder.

Akbar M, McLean M, Garcia-Melchor E, Crowe LA, McMillan P, Fazzi UG, Martin D, Arthur A, Reilly JH, McInnes IB, Millar NL.

PLoS One. 2019 Apr 23;14(4):e0215301. doi: 10.1371/journal.pone.0215301. eCollection 2019.

8.

Alopecia areata is characterised by dysregulation in systemic type 17 and type 2 cytokines, which may contribute to disease-associated psychological morbidity.

Bain KA, McDonald E, Moffat F, Tutino M, Castelino M, Barton A, Cavanagh J, Ijaz UZ, Siebert S, McInnes IB, Astrand A, Holmes S, Milling SWF.

Br J Dermatol. 2019 Apr 13. doi: 10.1111/bjd.18008. [Epub ahead of print]

PMID:
30980732
9.

Association between enthesitis and health-related quality of life in psoriatic arthritis in anti-TNF-naïve patients from two Phase 3 ustekinumab trials.

McInnes IB, Puig L, Gottlieb AB, Ritchlin C, Song M, You Y, Kafka S, Morgan GJ, Rahman P, Kavanaugh A; PSUMMIT 1 and 2 Study.

J Rheumatol. 2019 Apr 1. pii: jrheum.180792. doi: 10.3899/jrheum.180792. [Epub ahead of print]

PMID:
30936281
10.

Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients.

Humby F, Lewis M, Ramamoorthi N, Hackney JA, Barnes MR, Bombardieri M, Setiadi AF, Kelly S, Bene F, DiCicco M, Riahi S, Rocher V, Ng N, Lazarou I, Hands R, van der Heijde D, Landewé RBM, van der Helm-van Mil A, Cauli A, McInnes I, Buckley CD, Choy EH, Taylor PC, Townsend MJ, Pitzalis C.

Ann Rheum Dis. 2019 Jun;78(6):761-772. doi: 10.1136/annrheumdis-2018-214539. Epub 2019 Mar 16.

11.

Clinical applications of machine learning algorithms: beyond the black box.

Watson DS, Krutzinna J, Bruce IN, Griffiths CE, McInnes IB, Barnes MR, Floridi L.

BMJ. 2019 Mar 12;364:l886. doi: 10.1136/bmj.l886. No abstract available.

PMID:
30862612
12.

JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis.

Fragoulis GE, McInnes IB, Siebert S.

Rheumatology (Oxford). 2019 Feb 1;58(Supplement_1):i43-i54. doi: 10.1093/rheumatology/key276.

13.

Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naive patients with psoriatic arthritis.

Strand V, McInnes I, Mease P, Nash P, Thom H, Kalyvas C, Hunger M, Gandhi K, Pricop L, Jugl S, Choy E.

J Comp Eff Res. 2019 May;8(7):497-510. doi: 10.2217/cer-2018-0141. Epub 2019 Feb 26.

14.

Tranexamic acid toxicity in human periarticular tissues.

McLean M, McCall K, Smith IDM, Blyth M, Kitson SM, Crowe LAN, Leach WJ, Rooney BP, Spencer SJ, Mullen M, Campton JL, McInnes IB, Akbar M, Millar NL.

Bone Joint Res. 2019 Feb 2;8(1):11-18. doi: 10.1302/2046-3758.81.BJR-2018-0181.R1. eCollection 2019 Jan.

15.

Europe rules on harm from fluoroquinolone antibiotics.

Millar NL, Siebert S, McInnes IB.

Nature. 2019 Feb;566(7744):326. doi: 10.1038/d41586-019-00619-7. No abstract available.

PMID:
30783286
16.

Limits of traditional evidence-based medicine methodologies exemplified by the novel era in psoriatic arthritis drug development.

Leijten EF, Radstake TR, McInnes IB, Jacobs JW.

Expert Rev Clin Immunol. 2019 May;15(5):441-444. doi: 10.1080/1744666X.2019.1580144. Epub 2019 Feb 18. No abstract available.

PMID:
30729823
17.

S100A8 & S100A9: Alarmin mediated inflammation in tendinopathy.

Crowe LAN, McLean M, Kitson SM, Melchor EG, Patommel K, Cao HM, Reilly JH, Leach WJ, Rooney BP, Spencer SJ, Mullen M, Chambers M, Murrell GAC, McInnes IB, Akbar M, Millar NL.

Sci Rep. 2019 Feb 6;9(1):1463. doi: 10.1038/s41598-018-37684-3.

18.

Evidence of a causal relationship between body mass index and psoriasis: A mendelian randomization study.

Budu-Aggrey A, Brumpton B, Tyrrell J, Watkins S, Modalsli EH, Celis-Morales C, Ferguson LD, Vie GÅ, Palmer T, Fritsche LG, Løset M, Nielsen JB, Zhou W, Tsoi LC, Wood AR, Jones SE, Beaumont R, Saunes M, Romundstad PR, Siebert S, McInnes IB, Elder JT, Davey Smith G, Frayling TM, Åsvold BO, Brown SJ, Sattar N, Paternoster L.

PLoS Med. 2019 Jan 31;16(1):e1002739. doi: 10.1371/journal.pmed.1002739. eCollection 2019 Jan.

19.

Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials.

Schreiber S, Colombel JF, Feagan BG, Reich K, Deodhar AA, McInnes IB, Porter B, Das Gupta A, Pricop L, Fox T.

Ann Rheum Dis. 2019 Apr;78(4):473-479. doi: 10.1136/annrheumdis-2018-214273. Epub 2019 Jan 23.

20.

In vivo multiplex molecular imaging of vascular inflammation using surface-enhanced Raman spectroscopy.

Noonan J, Asiala SM, Grassia G, MacRitchie N, Gracie K, Carson J, Moores M, Girolami M, Bradshaw AC, Guzik TJ, Meehan GR, Scales HE, Brewer JM, McInnes IB, Sattar N, Faulds K, Garside P, Graham D, Maffia P.

Theranostics. 2018 Nov 29;8(22):6195-6209. doi: 10.7150/thno.28665. eCollection 2018.

21.

Patient-reported outcomes and safety in patients undergoing synovial biopsy: comparison of ultrasound-guided needle biopsy, ultrasound-guided portal and forceps and arthroscopic-guided synovial biopsy techniques in five centres across Europe.

Just SA, Humby F, Lindegaard H, Meric de Bellefon L, Durez P, Vieira-Sousa E, Teixeira R, Stoenoiu M, Werlinrud J, Rosmark S, Larsen PV, Pratt A, Choy E, Gendi N, Buch MH, Edwards CJ, Taylor PC, McInnes IB, Fonseca JE, Pitzalis C, Filer A.

RMD Open. 2018 Oct 26;4(2):e000799. doi: 10.1136/rmdopen-2018-000799. eCollection 2018.

22.

JAK Inhibitors in Rheumatology: Implications for Paediatric Syndromes?

Kerrigan SA, McInnes IB.

Curr Rheumatol Rep. 2018 Nov 8;20(12):83. doi: 10.1007/s11926-018-0792-7. Review.

23.

Neutropaenia in early rheumatoid arthritis: frequency, predicting factors, natural history and outcome.

Fragoulis GE, Paterson C, Gilmour A, Derakhshan MH, McInnes IB, Porter D, Siebert S.

RMD Open. 2018 Oct 8;4(2):e000739. doi: 10.1136/rmdopen-2018-000739. eCollection 2018.

24.

Rheumatoid arthritis and depression: an inflammatory perspective.

Nerurkar L, Siebert S, McInnes IB, Cavanagh J.

Lancet Psychiatry. 2019 Feb;6(2):164-173. doi: 10.1016/S2215-0366(18)30255-4. Epub 2018 Oct 23. Review.

PMID:
30366684
25.

The extending scope of kinase inhibition in immune diseases.

McInnes IB, Siebert S.

Lancet. 2018 Dec 1;392(10162):2328-2331. doi: 10.1016/S0140-6736(18)32600-X. Epub 2018 Oct 22. No abstract available.

PMID:
30360966
26.

Why did IL-23p19 inhibition fail in AS: a tale of tissues, trials or translation?

Siebert S, Millar NL, McInnes IB.

Ann Rheum Dis. 2018 Oct 8. pii: annrheumdis-2018-213654. doi: 10.1136/annrheumdis-2018-213654. [Epub ahead of print] No abstract available.

27.

Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis.

McInnes IB, Nash P, Ritchlin C, Choy EH, Kanters S, Thom H, Gandhi K, Pricop L, Jugl SM.

J Comp Eff Res. 2018 Nov;7(11):1107-1123. doi: 10.2217/cer-2018-0075. Epub 2018 Sep 19.

28.

Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey.

Roodenrijs NMT, de Hair MJH, van der Goes MC, Jacobs JWG, Welsing PMJ, van der Heijde D, Aletaha D, Dougados M, Hyrich KL, McInnes IB, Mueller-Ladner U, Senolt L, Szekanecz Z, van Laar JM, Nagy G; whole EULAR Task Force on development of EULAR recommendations for the comprehensive management of difficult-to-treat rheumatoid arthritis.

Ann Rheum Dis. 2018 Dec;77(12):1705-1709. doi: 10.1136/annrheumdis-2018-213687. Epub 2018 Sep 7.

PMID:
30194273
29.

Expression of interleukin-18 in muscle tissue of patients with polymyositis or dermatomyositis and effects of conventional immunosuppressive treatment.

Helmers SB, Bruton M, Loell I, Ulfgren AK, Gracie AJ, McInnes IB, Lundberg IE.

Rheumatology (Oxford). 2018 Dec 1;57(12):2149-2157. doi: 10.1093/rheumatology/key222.

PMID:
30102381
30.

Characterization and Changes of Lymphocyte Subsets in Baricitinib-Treated Patients With Rheumatoid Arthritis: An Integrated Analysis.

Tanaka Y, McInnes IB, Taylor PC, Byers NL, Chen L, de Bono S, Issa M, Macias WL, Rogai V, Rooney TP, Schlichting DE, Zuckerman SH, Emery P.

Arthritis Rheumatol. 2018 Dec;70(12):1923-1932. doi: 10.1002/art.40680. Epub 2018 Oct 22.

PMID:
30058112
31.

Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study.

McInnes IB, Mease PJ, Schett G, Kirkham B, Strand V, Williams N, Fox T, Pricop L, Jugl SM, Gandhi KK; FUTURE 2 Study Group.

Arthritis Res Ther. 2018 Jun 7;20(1):113. doi: 10.1186/s13075-018-1610-3.

32.

Phenotypic and Transcriptomic Analysis of Peripheral Blood Plasmacytoid and Conventional Dendritic Cells in Early Drug Naïve Rheumatoid Arthritis.

Cooles FAH, Anderson AE, Skelton A, Pratt AG, Kurowska-Stolarska MS, McInnes I, Hilkens CMU, Isaacs JD.

Front Immunol. 2018 May 9;9:755. doi: 10.3389/fimmu.2018.00755. eCollection 2018.

33.

Correction to: Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison.

Nash P, McInnes IB, Mease PJ, Thom H, Hunger M, Karabis A, Gandhi K, Mpofu S, Jugl SM.

Rheumatol Ther. 2018 Dec;5(2):595. doi: 10.1007/s40744-018-0117-3.

34.

Genome-wide association study of response to methotrexate in early rheumatoid arthritis patients.

Taylor JC, Bongartz T, Massey J, Mifsud B, Spiliopoulou A, Scott IC, Wang J, Morgan M, Plant D, Colombo M, Orchard P, Twigg S, McInnes IB, Porter D, Freeston JE, Nam JL, Cordell HJ, Isaacs JD, Strathdee JL, Arnett D, de Hair MJH, Tak PP, Aslibekyan S, van Vollenhoven RF, Padyukov L, Bridges SL, Pitzalis C, Cope AP, Verstappen SMM, Emery P, Barnes MR, Agakov F, McKeigue P, Mushiroda T, Kubo M, Weinshilboum R, Barton A, Morgan AW, Barrett JH; MATURA; and PAMERA; Consortia.

Pharmacogenomics J. 2018 Jul;18(4):528-538. doi: 10.1038/s41397-018-0025-5. Epub 2018 May 25. Review.

35.

The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis.

Veale DJ, McGonagle D, McInnes IB, Krueger JG, Ritchlin CT, Elewaut D, Kanik KS, Hendrikx T, Berstein G, Hodge J, Telliez JB.

Rheumatology (Oxford). 2019 Feb 1;58(2):197-205. doi: 10.1093/rheumatology/key070.

36.

Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison.

Nash P, McInnes IB, Mease PJ, Thom H, Hunger M, Karabis A, Gandhi K, Mpofu S, Jugl SM.

Rheumatol Ther. 2018 Jun;5(1):99-122. doi: 10.1007/s40744-018-0106-6. Epub 2018 Mar 31. Erratum in: Rheumatol Ther. 2018 Dec;5(2):595.

37.

Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3).

Nash P, Mease PJ, McInnes IB, Rahman P, Ritchlin CT, Blanco R, Dokoupilova E, Andersson M, Kajekar R, Mpofu S, Pricop L; FUTURE 3 study group.

Arthritis Res Ther. 2018 Mar 15;20(1):47. doi: 10.1186/s13075-018-1551-x.

38.

Psoriatic arthritis: tissue-directed inflammation?

Cafaro G, McInnes IB.

Clin Rheumatol. 2018 Apr;37(4):859-868. doi: 10.1007/s10067-018-4012-7. Epub 2018 Feb 23. Review.

PMID:
29476352
39.

Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies.

Taylor PC, Kremer JM, Emery P, Zuckerman SH, Ruotolo G, Zhong J, Chen L, Witt S, Saifan C, Kurzawa M, Otvos JD, Connelly MA, Macias WL, Schlichting DE, Rooney TP, de Bono S, McInnes IB.

Ann Rheum Dis. 2018 Jul;77(7):988-995. doi: 10.1136/annrheumdis-2017-212461. Epub 2018 Feb 20.

40.

Antibiotics with Interleukin-15 Inhibition Reduce Joint Inflammation and Bone Erosions but Not Cartilage Destruction in Staphylococcus aureus-Induced Arthritis.

Bergmann B, Jirholt P, Henning P, Lindholm C, Ohlsson C, McInnes IB, Lerner UH, Gjertsson I.

Infect Immun. 2018 Apr 23;86(5). pii: e00960-17. doi: 10.1128/IAI.00960-17. Print 2018 May.

41.

ILDR2 Is a Novel B7-like Protein That Negatively Regulates T Cell Responses.

Hecht I, Toporik A, Podojil JR, Vaknin I, Cojocaru G, Oren A, Aizman E, Liang SC, Leung L, Dicken Y, Novik A, Marbach-Bar N, Elmesmari A, Tange C, Gilmour A, McIntyre D, Kurowska-Stolarska M, McNamee K, Leitner J, Greenwald S, Dassa L, Levine Z, Steinberger P, Williams RO, Miller SD, McInnes IB, Neria E, Rotman G.

J Immunol. 2018 Mar 15;200(6):2025-2037. doi: 10.4049/jimmunol.1700325. Epub 2018 Feb 5.

42.

Rheumatoid arthritis.

Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, Kavanaugh A, McInnes IB, Solomon DH, Strand V, Yamamoto K.

Nat Rev Dis Primers. 2018 Feb 8;4:18001. doi: 10.1038/nrdp.2018.1. Review.

PMID:
29417936
43.

Chromosome conformation signatures define predictive markers of inadequate response to methotrexate in early rheumatoid arthritis.

Carini C, Hunter E; Scottish Early Rheumatoid Arthritis Inception cohort Investigators, Ramadass AS, Green J, Akoulitchev A, McInnes IB, Goodyear CS.

J Transl Med. 2018 Jan 29;16(1):18. doi: 10.1186/s12967-018-1387-9.

44.

Corrigendum: The RA-MAP Consortium: a working model for academia-industry collaboration.

Cope AP, Barnes MR, Belson A, Binks M, Brockbank S, Bonachela-Capdevila F, Carini C, Fisher BA, Goodyear CS, Emery P, Ehrenstein MR, Gozzard N, Harris R, Hollis S, Keidel S, Levesque M, Lindholm C, McDermott MF, McInnes IB, Mela CM, Parker G, Read S, Pedersen AW, Ponchel F, Porter D, Rao R, Rowe A, Schulze-Knappe P, Sleeman MA, Symmons D, Taylor PC, Tom B, Tsuji W, Verbeeck D, Isaacs JD; RA-MAP Consortium.

Nat Rev Rheumatol. 2018 Jan 24;14(2):119. doi: 10.1038/nrrheum.2018.6.

PMID:
29362468
45.

Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor α Monoclonal Antibody: Long-Term Safety and Efficacy in Patients With Rheumatoid Arthritis.

Burmester GR, McInnes IB, Kremer JM, Miranda P, Vencovský J, Godwood A, Albulescu M, Michaels MA, Guo X, Close D, Weinblatt M.

Arthritis Rheumatol. 2018 May;70(5):679-689. doi: 10.1002/art.40420. Epub 2018 Mar 31.

46.

Visualising the interaction of CD4 T cells and DCs in the evolution of inflammatory arthritis.

Prendergast CT, Patakas A, Al-Khabouri S, McIntyre CL, McInnes IB, Brewer JM, Garside P, Benson RA.

Ann Rheum Dis. 2018 Apr;77(4):579-588. doi: 10.1136/annrheumdis-2017-212279. Epub 2018 Jan 22.

PMID:
29358281
47.

MicroRNA-155-at the Critical Interface of Innate and Adaptive Immunity in Arthritis.

Alivernini S, Gremese E, McSharry C, Tolusso B, Ferraccioli G, McInnes IB, Kurowska-Stolarska M.

Front Immunol. 2018 Jan 5;8:1932. doi: 10.3389/fimmu.2017.01932. eCollection 2017. Review.

48.

IL-11 facilitates a novel connection between RA joint fibroblasts and endothelial cells.

Elshabrawy HA, Volin MV, Essani AB, Chen Z, McInnes IB, Van Raemdonck K, Palasiewicz K, Arami S, Gonzalez M, Ashour HM, Kim SJ, Zhou G, Fox DA, Shahrara S.

Angiogenesis. 2018 May;21(2):215-228. doi: 10.1007/s10456-017-9589-y. Epub 2018 Jan 11.

49.

Driving chronicity in rheumatoid arthritis: perpetuating role of myeloid cells.

Alivernini S, Tolusso B, Ferraccioli G, Gremese E, Kurowska-Stolarska M, McInnes IB.

Clin Exp Immunol. 2018 Jul;193(1):13-23. doi: 10.1111/cei.13098. Epub 2018 Feb 2. Review.

50.

Corrigendum: Synovial tissue research: a state-of-the-art review.

Orr C, Vieira-Sousa E, Boyle DL, Buch MH, Buckley CD, Cañete JD, Catrina AI, Choy EHS, Emery P, Fearon U, Filer A, Gerlag D, Humby F, Isaacs JD, Just SA, Lauwerys BR, Goff BL, Manzo A, McGarry T, McInnes IB, Najm A, Pitzalis C, Pratt A, Smith M, Tak PP, Tas SW, Thurlings R, Fonseca JE, Veale DJ.

Nat Rev Rheumatol. 2017 Dec 19;14(1):60. doi: 10.1038/nrrheum.2017.206.

PMID:
29255214

Supplemental Content

Loading ...
Support Center